Skip to main content
Features
Assistant
AI grounded in research
Search
Full-text citation search
Collections
Organize and monitor papers
All Features →
Integrations
MCP
Connect AI agents to Scite
API
Programmatic data access
Holdings
Full-text via your library
Zotero Plugin
Citation data in Zotero
Browser Extension
Citation badges anywhere
All Integrations →
Data
Rankings
Pricing
Log In
Start Free Trial
Features
Assistant
AI grounded in research
Search
Full-text citation search
Collections
Organize and monitor papers
All Features →
Integrations
MCP
Connect AI agents to Scite
API
Programmatic data access
Holdings
Full-text via your library
Zotero Plugin
Citation data in Zotero
Browser Extension
Citation badges anywhere
All Integrations →
Data
Rankings
Pricing
Log In
Start Free Trial
E Bork
Sign up to set email alerts
16
Publications
200
Citation Statements Received
62
Citation Statements Given
How they've been cited
434
3
196
1
How they cite others
176
4
56
2
Affiliations
Bispebjerg Hospital
,
Rigshospitalet
Publications
Order By: Most citations
Double‐blind, placebo‐controlled, randomized study of chlorhexidine prophylaxis for 5‐fluorouracil‐based chemotherapy‐induced oral mucositis with nonblinded randomized comparison to oral cooling (cryotherapy) in gastrointestinal malignancies
Sørensen
1
,
Skovsgaard
2
,
Bork
3
et al.
2008
Cancer
Abstract
Show
82
1
94
0
Get access via publisher
Add to collection
Cite
Early detection of response in small cell bronchogenic carcinoma by changes in serum concentrations of creatine kinase, neuron specific enolase, calcitonin, ACTH, serotonin and gastrin releasing peptide
Bork
1
,
Hansen
2
,
Urdal
3
et al.
1988
European Journal of Cancer and Clinical Oncology
43
1
15
1
Get access via publisher
Add to collection
Cite
Elevated plasma concentrations of C-flanking gastrin-releasing peptide in small-cell lung cancer.
Holst
1
,
Hansen
2
,
Bork
3
et al.
1989
JCO
Abstract
Show
40
0
16
0
Get access via publisher
Add to collection
Cite
Teniposide (VM-26), an overlooked highly active agent in small-cell lung cancer. Results of a phase II trial in untreated patients.
Bork
1
,
Hansen
2
,
Dombernowsky
3
et al.
1986
JCO
Abstract
Show
74
0
15
0
Get access via publisher
Add to collection
Cite
A phase I clinical and pharmacokinetic study of brequinar sodium, DUP 785 (NSC 368390), using a weekly and a biweekly schedule
Bork
1
,
Vest
2
,
Hansen
3
1989
European Journal of Cancer and Clinical Oncology
27
0
10
0
Get access via publisher
Add to collection
Cite
Teniposide and etoposide in previously untreated small-cell lung cancer: a randomized study.
Bork
1
,
Ersbøll
2
,
Dombernowsky
3
et al.
1991
JCO
Abstract
Show
46
1
9
0
Get access via publisher
Add to collection
Cite
Mucocutaneous side effects of brequinar sodium. A new inhibitor of pyrimidine de novo biosynthesis
Schwartsmann
1
,
Bork
2
,
Vermorken
3
et al.
1989
Cancer
Abstract
Show
13
0
7
0
Get access via publisher
Add to collection
Cite
A phase I evaluation of N10-propargyl-5,8-dideazafolic acid
Vest
1
,
Bork
2
,
Hansen
3
1988
European Journal of Cancer and Clinical Oncology
17
0
7
0
Get access via publisher
Add to collection
Cite
1
2